Rekombinanter CD74 Antikörper

Produktnummer ABIN7828290

Der Kaninchen Monoklonal anti-CD74 Antikörper (Klon A535) (ABIN7828290) detektiert spezifisch CD74 in FACS, WB und IHC. Dieser Antikörper reagiert spezifisch mit Proben aus Human.

Kurzübersicht für Rekombinanter CD74 Antikörper (ABIN7828290)

Target: CD74 (HLA-DR-gamma (CD74))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser CD74 Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Western Blotting (WB), Immunohistochemistry (IHC)

Klon: A535

Produktdetails anti-CD74 Antikörper

Verwendungszweck: Recombinant CD74 Monoclonal Antibody

Aufreinigung: Protein A purified

Immunogen: Recombinant human CD74 fragment

Isotyp: IgG, kappa

Anwendungsinformationen

Applikationshinweise: WB 1:500-1:2000,IHC 1:2000-1:5000,FCM 1:50

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS, 50 % glycerol, 0.05 % Proclin 300, 0.05 % protein protectant.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.

Haltbarkeit: 12 months

Details zu CD74

Target: CD74 (HLA-DR-gamma (CD74))

Andere Bezeichnung: CD74

Hintergrund: HLA class II histocompatibility antigen gamma chain,HLADG,Ia antigen-associated invariant chain,Ia-GAMMA II,Ii,p33,CD74 HLA-DR antigens-associated invariant chain,DHLAG,CD74,invariant chain,CD 74,CD74 antigen,CD74 antigen (invariant polypeptide of major histocompatibility complex,CD74 Molecule,class II antigen-associated),class II invariant chain,CLIP,Gamma chain of class II antigens,HG2A,HLA DR antigens associated invariant chain,HLA DR gamma,HLADR antigens associated invariant chain,HLA-DR antigens-associated invariant chain,HLA-DR-gamma,Ia antigen associated invariant chain,Ia associated invariant chain,Ia gamma,Ia-GAMMA,Invariant polypeptide of major histocompatibility complex class II antigen associated,la-gamma,major histocompatibility complex,Major histocompatibility complex class II invariant chain,MHC HLA DR gamma chain,MHC HLA-DR gamma chain,p35,Protein 41,CD74,DHLAG,HLA class II histocompatibility antigen gamma chain,HLADG,Ia antigen-associated invariant chain,p33,CD 14,CD_antigen=CD14,CD14,CD14 antigen,CD14 Molecule,LPS-R,Mo2,Monocyte differentiation antigen CD14,Monocyte differentiation antigen CD14 urinary form,membrane-bound form,Myeloid cell specific leucine rich glycoprotein,Myeloid cell-specific leucine-rich glycoprotein,CD74, also known as the MHC Class II-associated invariant chain (Ii), is a type II transmembrane glycoprotein that plays a critical role in the antigen presentation process as a chaperone of MHC Class II proteins. It is expressed at high levels on B cells and to a lesser extent on numerous antigen presenting cell (APC) types including dendritic cells, Langerhans cells, monocytes, and macrophages as well as non-traditional APCs such as epithelial cells. CD74 was initially identified for its ability to regulate the folding and intracellular trafficking of newly synthesized MHC Class II molecules. Following expression, CD74 self-assembles as a trimer that serves as a scaffold for the assembly of MHC Class II molecules. Through this interaction, CD74 blocks the peptide binding cleft of MHC Class II molecules and prevents their premature association with endogenous polypeptides. Binding to CD74 also facilitates the translocation of MHC Class II molecules from the endoplasmic reticulum to the endocytic compartments during antigen presentation. Cat.No. Product Name Clone No. IF:{{item.impact}} Journal:{{item.journal}} ({{item.year}}) DOI:{{item.doi}} Reactivity:{{item.species}} Sample Type:{{item.sample_type}} Previous {{ page }} Next Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}} Previous {{ page }} Next [

Molekulargewicht:

Calculated MW: 34 kDa

Observed MW: 34 kDa

UniProt: P04233

Pathways: Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Negative Regulation of intrinsic apoptotic Signaling, Cancer Immune Checkpoints